Which statement best describes octreotide's effect on short bowel syndrome outcomes?

• A. Eliminates the need for parenteral nutrition
• B. Has short-lasting effects and has not been shown to improve absorption or eliminate parenteral nutrition
• C. Always improves intestinal absorption
• D. Increases the need for parenteral nutrition

Answer: (B)

Octreotide can modestly reduce intestinal secretions and slow transit, which may lower high-output stoma drainage in short bowel syndrome. However, these effects are typically short-lived and do not translate into a reliable improvement in nutrient absorption or a reduced need for parenteral nutrition over the long term. In other words, it may offer a temporary, situational benefit but has not been shown to provide sustained gains in absorption or to eliminate dependence on PN for most patients. This is why the best description is that its effects are short-lasting and not proven to improve absorption or remove the need for parenteral nutrition.